Cytori Therapeutics Inc. (CYTX) to Install Cell Bank in Hong Kong
Cytori Therapeutics Inc. is a leader in providing physicians and patients worldwide with medical technologies that harness the potential of adult regenerative cells from adipose tissue. The company’s Cellution System family of medical devices and instruments is currently being sold into the European and Asian cosmetic and reconstructive surgery markets. Its StemSource product line is sold globally for cell banking and research applications.
The company announced today that it will install a comprehensive StemSource Cell Bank in Hong Kong for Neo Derm Limited. Neo Derm is Hong Kong’s leading provider of medical aesthetic products and services with 18 treatment centers located in Hong Kong, Shanghai and elsewhere.
Building upon Neo Derm’s current use of Cytori’s Cellution System, the bank installation will be the first adipose cell and tissue bank in Hong Kong. With both adipose-derived stem and regenerative cell and tissue banking capabilities, the initial focus of the bank will be on the potential of aesthetic medicine. The bank will help fulfill demand for cell-enriched aesthetic procedures.
Cytori believes there is a lot of potential in the Hong Kong market. The company’s president Marc Hedrick said, “Natural aesthetic medicine represents a major growth opportunity in Hong Kong. We are pleased to be partnering with the leader in the field and look forward to growing this strategic relationship.”
For more information on Cytori Therapeutics, please visit the company’s website at cytori.com
Please see disclaimer on QualityStocks website: disclaimer.qualitystocks.net
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.